Identification and In-Depth Analysis of the Novel FGFR2-NDC80 Fusion in a Cholangiocarcinoma Patient: Implication for Therapy

Fibroblast growth factor receptor 2 (FGFR2) fusions have emerged as a new therapeutic target for cholangiocarcinoma in clinical practice following the United States Food and Drug Administration (FDA) approval of Pemigatinib in May 2020. FGFR2 fusions can result in a ligand-independent constitutive a...

Descripción completa

Detalles Bibliográficos
Autores principales: Scheiter, Alexander, Keil, Felix, Lüke, Florian, Grosse, Jirka, Verloh, Niklas, Opitz, Sabine, Schlosser, Sophie, Kandulski, Arne, Pukrop, Tobias, Dietmaier, Wolfgang, Evert, Matthias, Calvisi, Diego F., Utpatel, Kirsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025813/
https://www.ncbi.nlm.nih.gov/pubmed/33800328
http://dx.doi.org/10.3390/curroncol28020112

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025813/
https://www.ncbi.nlm.nih.gov/pubmed/33800328
http://dx.doi.org/10.3390/curroncol28020112

Ejemplares similares